Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Diamedica Inc (TSV: DMA)
4.630 CAD  UNCHANGED
Last Price  /  Updated: 1:27 PM EST, Jan 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 4.630
Bid (Size) 4.570 (25)
Ask (Size) 5.000 (12)
Prev. Close 4.630
Today's Range 4.630 - 4.630
52wk Range 3.330 - 9.350
Shares Outstanding 156,424,754
Dividend Yield N/A
Performance
YTD
+7.67%
+7.67%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-36.58%
-36.58%
Top News
More News
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development:... Read More
from GlobeNewswire News Releases
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, provided a business update... Read More
from GlobeNewswire News Releases
More News
Read More
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
from GlobeNewswire News Releases
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
from GlobeNewswire News Releases
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
from GlobeNewswire News Releases
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
from GlobeNewswire News Releases
DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
from GlobeNewswire News Releases
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
from GlobeNewswire News Releases
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
from GlobeNewswire News Releases
DiaMedica Closes Public Offering in the United States
from GlobeNewswire News Releases
DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.